Loading...
Patients with diabetes are at greater risk than patients without diabetes for in-stent restenosis and thrombotic events after cardiac revascularization. In this multicenter, randomized trial funded by the stent manufacturer, 200 diabetic patients in Germany were treated with either a sirolimus-eluting stent (SES) or a bare-metal stent (BMS). All patients had single, de novo lesions and received dual antiplatelet therapy (aspirin and clopidogrel) for at least 6 months. The mean reference vessel size and lesion length were 2.6 mm and 11 mm, respectively.
Follow-up angiography was performed at 8 months in 78% of patients. The primary study endpoint of mean late in-segment lumen loss was 0.17 mm with SES and 0.75 mm with BMS (P<0.0001). These lo…